Titles, dates, and times of these presentations appear below.
Tesetaxel: activity of an oral taxane as first-line treatment in metastatic breast cancer. Abstract #1016 Lead author: Andrew Seidman, MD, Memorial Sloan-Kettering Cancer Center Poster Discussion Session: Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy Monday June 4, 2012; 1:15-5:45PM
Phase II trial of tesetaxel, an oral taxane, as second-line therapy for patients with advanced gastroesophageal cancer. Abstract 4077 Lead author: Mary Mulcahy, MD, Northwestern University General Poster Session: Gastrointestinal (Non-colorectal) Cancer Monday June 4, 2012; 8AM-12N
Phase IB study of an all-oral chemotherapy regimen, tesetaxel plus capecitabine, in patients with advanced solid tumors. Abstract 3085 Lead author: Michael G. Martin, MD, West Clinic, Memphis, TN General Poster Session: Developmental Therapeutics - Experimental Therapeutics Monday June 4, 2012; 8:00AM-12:00N
Phase I development of a weekly dosing schedule for the oral taxane tesetaxel. Abstract 2555 Lead author: Amy Lang, MD, South Texas Accelerated Research Therapeutics General Poster Session: Developmental Therapeutics - Clinical Pharmacology and Immunotherapy Monday June 4, 2012; 8AM-1PM |